Al Gray

EUROFIMA European Company for the Financing of Railroad Rolling Stock engages in the business of providing finance services to railway equipment through borrowings and equity capital. The company's services encompass joint purchases, funding and lending. It also finances the acquisition and modernization of railway equipment. The company was founded on November 20, 1956 and is headquartered in Basel, Switzerland.

Extensa Group SA engages in the management of portfolio of offices, industrial, and logistics buildings. It specializes mixed use developments, urban regeneration, and larger suburban residential communities. The company was founded in 1910 and is headquartered in Brussels, Belgium.

Telenet NV provides telephone, television and internet services. It offers internet, television, telephone, mobile phone, entertainment services. The company was founded in October 1994 and is headquartered in Mechelen, Belgium.

Brussels Airport Co. SA operates and manages brussels airport. It offers flight information, timetable, special assistance, security and baggage and travel information for passenger. The firm’s business to business include aviation marketing, commercial partners, travel agents and tour operators and advertising at the airport. The company was founded in 1914 and is headquartered in Brussels, Belgium.

CropDesign NV develops traits for cereal crops. It delivers agronomic traits for the global commercial seed markets. The firm focuses on enhancing grain yield in crops such as corn and rice, and increasing biomass of energy crops. Its platform, TraitMill, lows evaluating the effect of genes on the performance of plants under different growing conditions, including drought and low nutrient stress. The company was founded in 1998 and is headquartered in Zwijnaarde, Blgium.

Vesalius Biocapital Partners SARL (Vesalius Biocapital Partners) is an independent venture capital firm founded in 2007 by Stéphane Verdood. The firm is headquartered in Luxembourg.

Apitope Technology (Bristol) Ltd. is a European biotech company developing therapeutic vaccines for treating autoimmune and allergic diseases, including multiple sclerosis, Type 1 diabetes, Graves' disease, allergies and organ transplant rejection. The team at Apitope is developing potential therapies intended to selectively treat the underlying cause of a range of autoimmune diseases rather than simply treat the disease symptoms or non-specifically suppress the whole immune system. Apitope's approach is based on well-established scientific evidence published in leading scientific journals showing that soluble, synthetic peptides can selectively suppress abnormal immune responses and reinstate the normal immune balance and thereby, tolerance. The firm's strategy is to position itself as a significant player in the therapeutic peptide space and make it a partner of choice for pharmaceutical companies keen to develop disease modifiers for autoimmune conditions. It has a highly experienced senior management team, with a proven track record in discovering and developing innovative compounds. The company's lead product candidate is under investigation for the potential treatment of multiple sclerosis and is currently in Phase I clinical development. It is partnered with Merck-Serono (a division of Merck KGaA, Darmstadt, Germany), one of the leading companies in the development and marketing of MS therapies.

ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands.

Société Anonyme de Participation et de Gestion is a holding company that engages in investment services. The company was founded on December 20, 1977 and is headquartered in Elsene, Belgium.

PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Part of Elia Group SA/NV, Elia Asset SA engages in power generation and distribution services. The company is based in Brussels, Belgium. The Belgian company was founded in 2001. The CEO is Christiaan Peeters.

Q-Biologicals NV operates as a bio pharma contract development and manufacturing organization. It provides process development and bio manufacturing services to customers in the biopharmaceutical industry. The company was founded in 2011 and is headquartered in Ghent, Belgium.

MaSTherCell SA engages in providing cell therapy manufacturing services. The company was founded in 2011 and is headquartered in Charleroi, Belgium.

Novadip Biosciences SA operates as a advanced biopharmaceutical company that develops cell-based therapies to treat patients with critical size bone defects and severe bone diseases. Its proprietary product, Creost, is a natural scaffold-free and tridimensional bone structure, which reconstructs large bone defects without the need of any biomaterial. The firm is a osteogenic living implant with a mineralization similar to a real bone. Its Creost is an autologous cell based-therapy product obtained from Adipose-derived Mesenchymal Stem Cells (AMSCs) which promotes (i) a perfect engraftment without any scaffold and (ii) a tissue remodeling with all native bone properties. Novadip Biosciences was founded by Jean-Fran?ois Pollet and Denis Dufrane in 2013 and is headquartered in Louvain-la-Neuve, Belgium.

Bioxodes SA develops pharmaceutical products. Its programme Ir-CPI, is the first in a novel class of antithrombotics, and is developed for the prevention of thrombosis in a range of applications including cardiopulmonary bypass grafting and percutaneous coronary intervention. The company was founded by Edmond Godfroid and Michel Guyaux on April 20, 2010 and is headquartered in Marche-en-Famenne, Belgium.

Fund+ is an independent Venture Capital firm founded in 2015. The firm is headquartered in Leuven, Belgium.

Bio-Sourcing SA develops and markets biological drugs for veterinary use. The firm focuses on farm animal health and companion animal health. The company was founded by Bertrand Mérot in June 2011 and is headquartered in Liege, Belgium.

Pharmafluidics NV develops micro chip liquid chromatography cartridges for analysis of complex biological samples. The company was founded by Wim De Malsche, Joeri Denayer, Gert Desme and Paul Godelieve Jacobs in 2010 and is headquartered in Ghent, Belgium.

DIM3 SA develops decision support application software and medical devices. The firm offers Scorso, an app for the screening and follow-up of disease-related malnutrition; Nutrow, a decision support software for an optimization of clinical nutrition; and Biocorder, a connected clinical mobile assistant. The company was founded by Jean Claude Havaux on September 23, 2004 and is headquartered in Liege, Belgium.

Ncardia SA engages in drug discovery research and development. Its cardiac products encompass hiPSC-derived Pluricyte, Cardiomyocytes, Cor.4U cardiomyocytes and vCor.4U ventricular cardiomyocytes and FibroCor.4U cardiac fibroblasts. The company is headquartered in Gosselies, Belgium.

Part of Ackermans & van Haaren NV, Voltis NV retails lighting articles, telecommunications, and electrical household appliances. The Belgian company also wholesale and installs electrical equipment materials.

Newton Biocapital Partners SPRL is an Independent Venture Capital firm founded in 2017 by Alain Parthoens. Newton Biocapital Partners SPRL is headquartered in Woluwe-Saint-Pierre.

EPICS Therapeutics SA engages in the development of therapeutic solutions for cancer. The company was founded by Jean Combalbert, Alain Parthoens and Francois Fuks on February 20, 2018 and is headquartered in Charleroi, Belgium.

Armeos NV is a Belgian company that specializes in the protection and management of harmful organizations. The company is based in Nivelles, Belgium, and has subsidiaries in Belgium, France, and Poland. The company brings nature back into balance when it requires assistance. Armeos was founded in 2017, and the CEOs are Jean Klimis and Pierre Klimis.

NeuVasQ Biotechnologies SA develops pharmaceutical products to treat neurological disorders by repairing neurovascular function. The company is based in Gosselies, Belgium. The Belgian company was founded in 2021 by Benoit Vanhollebeke.

Ncardia Holding SA provides biotech research and development, business management consulting, technical testing, and administrative services. The private company is based in Mont-Saint-Guibert, Belgium. The Belgian company was founded in 2014. Stefan Braam has been the CEO of the company since 2015.

Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation.